Diabetics prone to colon cancer

Heilungschancen bei

The connection between diabetes and colon cancer has now been scientifically proven. Researchers from Cancer Research UH and the Medical Research Council found that Tpy II diabetics are up to 3 times more likely to develop colon cancer. In their test, they examined blood samples from 10,000 men and women between the ages of 45 and 79. After 6 years, their state of health was checked again.

The conclusion of the study: Diabetics and people with abnormal glucose metabolism values ​​have a significantly higher risk of developing colon cancer than people with normal blood sugar values. Men are more affected by this tendency than women. The lead scientist Kay-Tee Khaw suspects that the same predisposing factors act in both diabetes and colon cancer. According to Kay-Tee Khaw, hormonal changes associated with diabetes have a positive effect on tumor growth.

A Swedish research group at the Karolinska Institute in Stockholm came to a similar conclusion. In a long-term study, the scientists examined 45,550 men over 6 years. Their result: the likelihood of developing colon or rectal cancer is almost 50 percent higher in men with diabetes than in non-diabetics of the same age.

As a consequence, the scientists are calling for diabetics to be examined for intestinal carcinoma immediately after diagnosis – before the blood sugar level is adjusted.

Since the organs react less and less to insulin during the development of type II diabetes, the blood of these still symptom-free people has, however, had an increased concentration of insulin for years (prediabetes). Since the latest findings, insulin has been suspected of being a powerful growth factor for cancer cell growth. It is already known that insulin activates a motor for cell division – the insulin-like growth factor (IGF). The insulin not only promotes its effect, but also occupies binding proteins that otherwise tend to block the IGF in a regulating manner. This interaction favors the cancer-promoting effect.

Adresse:

Im Bieth 36

69124 Heidelberg

Telefon: +49 6221-43540-30

bb

Fax: +49 6221-43540-29

© 2007-2021 MedVec International GmbH, Germany
de_DEGerman